Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Synergistic Effects of Naringenin and Metformin on Dyslipidemia and Glucose Regulation in High Fructose-Fed Rats

View through CrossRef
Background: Excessive intake of fructose can lead to insulin resistance (IR). Metformin is commonly used as a first-line treatment for type 2 diabetes, and naringenin, a flavonoid known for its anti-inflammatory properties, can potentially improve insulin resistance. However, the effects of combining these two treatments have not been evaluated. Therefore, the present study aims to investigate the combined effects of naringenin and metformin on fructose-induced insulin resistance in male rats. Materials and Methods: Male Wistar rats were divided into five groups: control (without receiving fructose), fructose-induced insulin resistance; F group (with receiving fructose for 8 weeks), fructose+metformin; FM (receiving metformin for last 4 weeks), fructose+naringenin; FN (receiving naringenin for last 4 weeks) and fructose+metformine+naringenin; FMN (receiving metformin and naringenin for last 4 weeks). At the end of the experiment, after an oral glucose tolerance test (OGTT), following deep anesthesia, blood drawing was performed to measure glucose, insulin, total cholesterol (TC), high-density lipoprotein-cholesterol (HDL-C), low-density lipoprotein-cholesterol (LDL-C), triglyceride (TG), tumor necrosis factor-alpha (TNF-a), interleukin 6 (IL-6), free fatty acid (FFA), homeostatic model assessment for insulin resistance (HOMA-IR), quantitative insulin sensitivity check index (QUICKI), and liver enzymes. Results: Although metformin and naringenin each alone showed anti-hyperglycemic effects, combined treatment of metformin with naringenin could more remarkably improve glucose intolerance, decrease glucose, TNF-alpha, IL-6, FFA, TG, and TG/HDL-C ratio, and alanine aminotransferase in FMN group compared to F group (P < .05 to P < .0001). Conclusion: Our findings demonstrated that the combination therapy of metformin and naringenin, as a novel therapeutic approach, reduced insulin resistance by improving glucose and lipid metabolism, as well as inhibiting inflammation.
Title: Synergistic Effects of Naringenin and Metformin on Dyslipidemia and Glucose Regulation in High Fructose-Fed Rats
Description:
Background: Excessive intake of fructose can lead to insulin resistance (IR).
Metformin is commonly used as a first-line treatment for type 2 diabetes, and naringenin, a flavonoid known for its anti-inflammatory properties, can potentially improve insulin resistance.
However, the effects of combining these two treatments have not been evaluated.
Therefore, the present study aims to investigate the combined effects of naringenin and metformin on fructose-induced insulin resistance in male rats.
Materials and Methods: Male Wistar rats were divided into five groups: control (without receiving fructose), fructose-induced insulin resistance; F group (with receiving fructose for 8 weeks), fructose+metformin; FM (receiving metformin for last 4 weeks), fructose+naringenin; FN (receiving naringenin for last 4 weeks) and fructose+metformine+naringenin; FMN (receiving metformin and naringenin for last 4 weeks).
At the end of the experiment, after an oral glucose tolerance test (OGTT), following deep anesthesia, blood drawing was performed to measure glucose, insulin, total cholesterol (TC), high-density lipoprotein-cholesterol (HDL-C), low-density lipoprotein-cholesterol (LDL-C), triglyceride (TG), tumor necrosis factor-alpha (TNF-a), interleukin 6 (IL-6), free fatty acid (FFA), homeostatic model assessment for insulin resistance (HOMA-IR), quantitative insulin sensitivity check index (QUICKI), and liver enzymes.
Results: Although metformin and naringenin each alone showed anti-hyperglycemic effects, combined treatment of metformin with naringenin could more remarkably improve glucose intolerance, decrease glucose, TNF-alpha, IL-6, FFA, TG, and TG/HDL-C ratio, and alanine aminotransferase in FMN group compared to F group (P < .
05 to P < .
0001).
Conclusion: Our findings demonstrated that the combination therapy of metformin and naringenin, as a novel therapeutic approach, reduced insulin resistance by improving glucose and lipid metabolism, as well as inhibiting inflammation.

Related Results

Metabolic Effects of Fructose and the Worldwide Increase in Obesity
Metabolic Effects of Fructose and the Worldwide Increase in Obesity
While virtually absent in our diet a few hundred years ago, fructose has now become a major constituent of our modern diet. Our main sources of fructose are sucrose from beet or ca...
Abstract 4965: Metformin has an anticancer effect by repressing TWIST/N-cadherin signaling.
Abstract 4965: Metformin has an anticancer effect by repressing TWIST/N-cadherin signaling.
Abstract Introduction and Objective. Metformin, one of the most commonly used medications for treatment of type 2 diabetes, has emerged as a potential anticancer age...
SAT031 The Effect Of Metformin On Increasing Glucose Metabolism And Secretion In The Distal Intestine
SAT031 The Effect Of Metformin On Increasing Glucose Metabolism And Secretion In The Distal Intestine
Abstract Disclosure: J. Nam: None. C. Kang: None. J. Oh: None. E. Wang: None. S. Lee: None. J. Hong: None. E. Lee: None. C. Ku: None. Object: Although...
Fructose Amplifies Counterregulatory Responses to Hypoglycemia in Humans
Fructose Amplifies Counterregulatory Responses to Hypoglycemia in Humans
Glucokinase (GK) is required for cellular glucose sensing, although there is a paucity of data regarding its role in the counterregulatory response to hypoglycemia in humans. Becau...
Fasting blood glucose predicts response to extended‐release metformin in gestational diabetes mellitus
Fasting blood glucose predicts response to extended‐release metformin in gestational diabetes mellitus
BackgroundMetformin is increasingly accepted as an alternative to insulin therapy in gestational diabetes mellitus (GDM). The Metformin in Gestational Diabetes (MiG) trial reported...

Back to Top